In Brief: Circon/U.S. Surgical
This article was originally published in The Gray Sheet
Executive Summary
Circon/U.S. Surgical: Circon shareholders elect two USSC-nominated board members to Circon's seven member board of directors in furtherance of USSC's hostile bid to take over the firm, according to a preliminary tabulation of Circon's Oct. 6 shareholder vote by independent inspector of the election Corporation Trust Company. Circon shareholders also appear to have adopted a USSC-sponsored, non-binding resolution to auction Circon to the highest bidder. Circon in late August rejected USSC's most recent tender offer of $16.50 per share, which will expire Oct. 23. USSC's first effort to buy Circon was an $18-per-share bid in August 1996. USSC has filed suit against Circon seeking to enjoin the company from reappointing Chairman and CEO Richard Auhll to the board ("The Gray Sheet" Sept. 22, In Brief)...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.